A lipid-modified estrogen derivative that treats breast cancer independent of estrogen receptor expression through simultaneous induction of autophagy and apoptosis

Molecular Cancer Research

Volumn 9, Issue 3, 2011, Pages 364-374

  Sinha, Sutapa ^a   Roy, Sayantani ^b   Reddy, Bathula Surendar ^b,c   Pal, Krishnendu ^b   Sudhakar, Godeshala ^b   Iyer, Seethalakshmi ^a   Dutta, Shamit ^a   Wang, Enfeng ^a   Vohra, Pawan Kumar ^a   Roy, Karnati Rammohan ^d   Reddanna, Pallu ^d   Mukhopadhyay, Debabrata ^a   Banerjee, Rajkumar ^a,b  

^a MAYO CLINIC   (United States)

^b INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

^d UNIVERSITY OF HYDERABAD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ESC 8; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CELL KILLING; CONTROLLED STUDY; DRUG EFFECT; DRUG SYNTHESIS; IN VIVO STUDY; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BREAST NEOPLASMS; CARCINOGENICITY TESTS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CELL SURVIVAL; ESTROGENS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; RATS; RATS, WISTAR; RECEPTORS, ESTROGEN; TOR SERINE-THREONINE KINASES;

EID: 79952829037     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0526     Document Type: Article

References (38)

1. Cleator SJ, Ahamed E, Coombes RC, Palmieri C. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer 2009;9Suppl 1:S6-17.
2. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998;51:227-38. (Pubitemid 29054556)
3. Boivin RP, Luu-The V, Lachance R, Labrie F, Poirier D. Structure-activity relationships of 17alpha-derivatives of estradiol as inhibitors of steroid sulfatase. J Med Chem 2000;43:4465-78. (Pubitemid 32046871)
4. Brueggemeier RW, Bhat AS, Lovely CJ, Coughenour HD, Joomprabutra S, Weitzel DH, et al. 2-Methoxymethylestradiol: a new 2-methoxy estrogen analog that exhibits antiproliferative activity and alters tubulin dynamics. J Steroid Biochem Mol Biol 2001;78:145-56. (Pubitemid 32879330)
5. Cushman M, He HM, Katzenellenbogen JA, Lin CM, Hamel E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem 1995;38:2041-9.
6. Jones GB, Hynd G, Wright JM, Purohit A, Plourde GW II, Huber RS, et al. Target-directed enediynes: designed estramycins. J Org Chem 2001;66:3688-95. (Pubitemid 32867606)
7. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2003;2:205-13. (Pubitemid 37361665)
8. Kasiotis KM, Mendorou C, Haroutounian SA, Alexis MN. High affinity 17alpha-substituted estradiol derivatives: synthesis and evaluation of estrogen receptor agonist activity. Steroids 2006;71:249-55. (Pubitemid 43208961)
9. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res 1990;50:4177-89. (Pubitemid 20225648)
10. Mitra K, Marquis JC, Hillier SM, Rye PT, Zayas B, Lee AS, et al. A rationally designed genotoxin that selectively destroys estrogen receptor-positive breast cancer cells. J Am Chem Soc 2002;124:1862-3. (Pubitemid 34215297)
11. Purohit A, Hejaz HA, Walden L, MacCarthy-Morrogh L, Packham G, Potter BV, et al. The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours. Int J Cancer 2000;85:584-9. (Pubitemid 30075140)
12. Rao PN, Cessac JW, Tinley TL, Mooberry SL. Synthesis and antimitotic activity of novel 2-methoxyestradiol analogs. Steroids 2002;67:1079-89. (Pubitemid 35341726)
13. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
14. Chia S, Gradishar W. Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer. Breast 2008;17Suppl 3:S16-21.
15. Peng J, Sengupta S, Jordan VC. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents Med Chem 2009;9:481-99.
16. Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 2008;63:163-81. (Pubitemid 351612435)
17. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-6. (Pubitemid 28406817)
18. Ravikumar B, Berger Z, Vacher C, O'Kane CJ, Rubinsztein DC. Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet 2006;15:1209-16.
19. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004;36:585-95. (Pubitemid 38715985)
20. Schoenlein PV, Periyasamy-Thandavan S, Samaddar JS, Jackson WH, Barrett JT. Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance. Autophagy 2009;5:400-3.
21. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005;5:726-34. (Pubitemid 41486365)
22. Bursch W, Ellinger A, Kienzl H, Török L, Pandey S, Sikorska M, et al. Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 1996;17:1595-607. (Pubitemid 26280381)
23. Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004;6:463-77. (Pubitemid 38456176)
24. Sato K, Tsuchihara K, Fujii S, Sugiyama M, Goya T, Atomi Y, et al. Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res 2007;67:9677-84. (Pubitemid 47621214)
25. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997;17:5629-39. (Pubitemid 27357659)
26. Pal S, Datta K, Khosravi-Far R, Mukhopadhyay D. Role of protein kinase Czeta in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. J Biol Chem 2001;276:2395-403.
27. Reddy BS, Banerjee R. 17Beta-estradiol-associated stealth-liposomal delivery of anticancer gene to breast cancer cells. Angew Chem Int Ed Engl 2005;44:6723-7. (Pubitemid 41532221)
28. Tanida I, Ueno T, Kominami E. LC3 and Autophagy. Methods Mol Biol 2008;445:77-88.
29. Munafo DB, Colombo MI. A novel assay to study autophagy: regulation of autophagosome vacuole size by amino acid deprivation. J Cell Sci 2001;114:3619-29. (Pubitemid 33041044)
30. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007;3:542-5. (Pubitemid 350060049)
31. Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ 2002;9:99-100. (Pubitemid 34144768)
32. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003;22:8983-98. (Pubitemid 38121699)
33. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42.
34. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237-8. (Pubitemid 15170469)
35. Lipton A, Harvey HA, Hamilton RW. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 1984;68:887-9. (Pubitemid 14082223)
36. Mukherjee A, Narayan KP, Pal K, Kumar JM, Rangaraj N, Kalivendi SV, et al. Selective cancer targeting via aberrant behavior of cancer cell-associated glucocorticoid receptor. Mol Ther 2009;17:623-31.
37. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-8. (Pubitemid 41161231)
38. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26:1932-40. (Pubitemid 46474636)